Videos

Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations
Final Analysis of the Phase 3 MAGNITUDE Trial

Featuring Elena Castro, MD, PhD

11/01/2023

Elena Castro, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the final analysis of the phase 3 MAGNITUDE trial. This study compared niraparib plus abiraterone acetate and prednisone (AAP) with placebo plus AAP among patients with metastatic castration-resistant prostate cancer (CRPC) and homologous recombination repair (HRR) gene alterations.

In this trial, Dr Castro stated, “we have seen an overall survival benefit from the combination [of abiraterone plus niraparib] for patients with BRCA1 and BRCA2 mutations." She added, "We should make the effort of identifying all our patients with BRCA mutations to offer them treatment with a PARP inhibitor as soon as possible."

These results were first presented by Kim Nguyen Chi, MD, BC Cancer and Vancouver Prostate Centre at University of British Columbia, Vancouver, British Columbia, Canada, at the 2023 European Society for Medical Oncology Annual Congress in Madrid, Spain.

Transcript:

Hi, my name is Elena Castro. I'm a medical oncologist at Hospital University 12 de Octubre in Madrid, Spain. At ESMO 2023, the final results of the overall survival of the MAGNITUDE study have been presented.

MAGNITUDE is a randomized phase 3 study that investigated the benefit of combining abiraterone and niraparib in first-line treatment of metastatic castration-resistant prostate cancer. Patients were screened for alterations in HRR genes. Those patients who presented at least 1 alteration in these genes were included in cohort 1, and patients without any alterations were included in cohort 2. Within each cohort, patients were randomized to receive abiraterone alone or in combination with niraparib. The primary objective of this study was radiographic progression-free survival.

A futility analysis of the study suggested no benefit from the combination in cohort 2, patients without HRR alterations, and that cohort was closed. For patients with alterations in HRR genes, the primary objective was met with a benefit in [radiographic progression-free survival] rPFS from the combination of niraparib and abiraterone. Those results have already been presented in prior meetings.

Now we have learned the final results of the overall survival analysis. In a meta-analysis that included different risk factor and accounted for some imbalances in the populations observed in the treatment and control arms, we have seen a benefit and overall survival benefit from the combination for patients with BRCA1 and BRCA2 mutations. This is very important because we know that these patients have very poor outcomes when conventionally treated with taxanes or hormonal agents that we use for the treatment of mCRCP patients.

I think from now on, we should make the effort of identifying all our patients with BRCA mutations to offer them treatment with a PARP inhibitor as soon as possible.

Source:

Chi KNN, Castro E, Attard G, et al. Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. Presented at 2023 ESMO Annual Congress; October 20-24, 2023; Madrid, Spain. LBA85

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Recent News

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology

Conference Coverage

Biomarkers With Alectinib for ALK-Positive Non-Small Cell Lung Cancer

09/10/2024

Allison Casey ;

According to exploratory biomarker analyses from the phase 3 ALINA trial, there was a benefit to disease-free survival with alectinib regardless of EML4-ALK variant among patients with NSCLC.

According to exploratory...

09/10/2024

Oncology

Conference Coverage

Inhaled Corticosteroids to Reduce Radiation-Induced Pneumonitis Among Patients With Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that the addition of inhaled corticosteroids with radiotherapy significantly reduced the incidence of radiation-induced pneumonitis among patients with non-small cell lung cancer.

Results from a phase 2 study...

09/10/2024

Oncology

Conference Coverage

Neoadjuvant Nivolumab Demonstrated Promising Efficacy and Safety Among Patients With High-Risk Early Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2 POTENTIAL study, neoadjuvant nivolumab demonstrated efficacy and safety among patients with stage I non-small cell lung cancer, at high-risk of recurrence.

According to results from the...

09/10/2024

Oncology

Conference Coverage

Zipalertinib Demonstrated Promising Anti-Tumor Activity Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer

09/10/2024

Stephanie Holland ;

According to results from the phase 2b REZILIENT1 study, zipalertinib demonstrated promising anti-tumor activity among patients with EGFR exon 20 insertion-mutated non-small cell lung cancer who experienced disease progression after treatment...

According to results from the...

09/10/2024

Oncology

Conference Coverage

Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer

09/09/2024

Allison Casey ;

Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.

Ivonescimab showed a clinically...

09/09/2024

Oncology

Conference Coverage

Tifcemalimab Plus Toripalimab Demonstrated Promising Antitumor Activity For Refractory Extensive-Stage Small Cell Lung Cancer

09/09/2024

Stephanie Holland ;

According to phase 1/2 study results, tifcemalimab plus toripalimab showed promising antitumor activity with a manageable safety profile among patients with refractory extensive-stage small cell lung cancer.

According to phase 1/2 study...

09/09/2024

Oncology